HTS and Rational Drug Design [RDD] to Generate a Class of 5-HT2C-Selective Ligands for Possible Use in Schizophrenia by Kozikowski, Alan P. et al.
HTS and Rational Drug Design [RDD] to Generate a Class of 5-
HT2C-Selective Ligands for Possible Use in Schizophrenia
Alan P. Kozikowski,
Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, College of
Pharmacy University of Illinois at Chicago, Illinois 60612-7230 (USA)
Sung Jin Cho,
Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, College of
Pharmacy University of Illinois at Chicago, Illinois 60612-7230 (USA)
Niels H. Jensen,
Departments of Pharmacology and Psychiatry, Comprehensive Cancer Center, Center for
Neurobiology, Division of Medicinal Chemistry and Natural Products and NIMH Psychoactive Drug
Screening Program, University of North Carolina Medical School, Chapel Hill CB 7365, North
Carolina 27599 (USA)
John A. Allen,
Departments of Pharmacology and Psychiatry, Comprehensive Cancer Center, Center for
Neurobiology, Division of Medicinal Chemistry and Natural Products and NIMH Psychoactive Drug
Screening Program, University of North Carolina Medical School, Chapel Hill CB 7365, North
Carolina 27599 (USA)
Andreas M. Svennebring, and
Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, College of
Pharmacy University of Illinois at Chicago, Illinois 60612-7230 (USA)
Bryan L. Roth
Departments of Pharmacology and Psychiatry, Comprehensive Cancer Center, Center for
Neurobiology, Division of Medicinal Chemistry and Natural Products and NIMH Psychoactive Drug
Screening Program, University of North Carolina Medical School, Chapel Hill CB 7365, North
Carolina 27599 (USA)
Keywords
CNS; Drug Discovery; 5-HT2C; Medicinal Chemistry; Schizophrenia
The 5-hydroxytryptamine (1, 5-HT) 2C receptor (5-HT2C), a prominent central serotonin
receptor subtype, is widely distributed throughout the central nervous system (CNS) and is
thought to play a role in regulating a wide variety of behavioral processes such as mood,
appetite, and sexual behavior.[1-4] The 5-HT2A receptor mediates the hallucinogenic activity
of drugs such as lysergic acid diethylamide (LSD) and is a major target for treating
schizophrenia, insomnia and other disorders.[5-8] The 5-HT2B receptor mediates the
potentially lethal valvulopathic side effects of several compounds that were used as prescription
drugs.[9,10]
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5-HT2C agonists have demonstrated efficacy in preclinical models of depression, obesity,
addiction, and psychosis.[11-13] Targeting the 5-HT2C receptor thus appears to offer a
promising means for developing novel therapeutics for the treatment of CNS related disorders.
However, as this receptor is homologous to the two other family members, 5-HT2A and 5-
HT2B,[14] it is essential that 5-HTHT2C agonists being developed for clinical use show little
if any activity at these subtypes.[15] To date, several 5-HTHT2C agonists have shown efficacy
in preclinical animal models (Figure 1),[16-18] and are currently undergoing human trials.
[16] In particular, one of the most advanced 5-HT2C ligands is Lorcaserin (2) which is being
developed by Arena Pharmaceuticals and which has been demonstrated in two Phase III trials
to be an orally active, antiobesity medication.[19]
Based upon the identification of tranylcypromine as the initial hit from an HTS campaign
employing a library of FDA approved drugs, we undertook a structural optimization campaign
that led to a potent, but moderately selective agonist 8 with 120- and 14-fold selectivity over
5-HT2A and 5-HT2B, respectively (EC50 = 585, 65, and 4.8 nM at the 2A, 2B, and 2C subtypes,
respectively). Compound 8 (10–60 mg/kg) was also demonstrated to exhibit moderate
antidepressant-like effects in a commonly used behavioral assay.[18]
However, because compound 8 fails to exhibit sufficient selectivity over the 5-HT2B receptor,
further optimization was required to identify a potential clinical candidate. Currently, the
degree of selectivity that is actually needed to avoid side effects is unknown, however, this is
a question that can ultimately be addressed only by studies in humans. Thus, we explored
additional, selected modifications of these trans-2-phenylcyclopropylmethylamine analogues
in order to improve upon this subtype selectivity issue. Our efforts to modify the 5-HT2C
agonist 8 led to the discovery of several new drug candidates with an increased subtype
selectivity including dual 5-HT2B antagonism / 5-HTHT2C agonism in the functional assays,
and which were thus found suitable for in vivo testing as detailed herein.
By stepwise structural modifications of the trans-(2-arylcyclopropyl)methylamine aromatic
moiety, we found that potent, 5-HT2C-selective compounds could be produced using 5-hydroxy
or 5-fluoro substituted systems with a medium sized 2-alkyloxy group. The 2-
cyclopropylmethyloxy-5-fluoro substituted derivative 12 was synthesized according to the
steps shown in Scheme 1. Thus, the starting compound 9 was prepared by employing a standard
sequence of reactions as previously reported.[18] The amino group of the phenolic derivative
9 was protected using Boc-anhydride. The N-Boc protected derivative 10 was then alkylated
with cyclopropylmethyl bromide followed by subsequent deprotection to provide the racemic
compound 12.
To synthesize the 2-cyclopropylmethyloxy-5-hydroxy substituted derivative 18, the 2-
cyclopropylmethyloxy intermediate 16 was prepared in a straightforward manner through a
sequence of selective protection and alkylation steps.[20] Next, the pivaloyl and Boc protecting
groups were removed sequentially to afford the final product 18 (Scheme 2).
To prepare the optically pure enantiomers of 12 (Scheme 3), we first carried out a chiral
separation of the N-Boc protected fluoro derivative 11 using a Chiralpack AD column. Under
isocratic conditions (4% isopropanol in hexane), the individual enantiomers could be
conveniently separated in pure form (> 99%). Due to the high resolution, stacked injections
could be employed in order to increase throughput. The choice of intermediate 11 on which to
carry out the chiral separation was based on the ease of the separation and the ready cleavage
of the resulting enantiomers under acidic conditions.
The resulting enantiomers (+)-11 and (−)-11 were then converted individually to (−)- and (+)-
trans-[2-(2 cyclopropylmethyloxy-5-fluorophenyl)cyclopropyl]-methylamine hydrochlorides
((−)-12 and (+)-12), respectively, using the same method as described above for the racemate.
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For preparation of the pure enantiomers of compound 18, intermediate 17 was used for the
chiral separation.
The functional activity of these two sets of compounds was determined by measuring Gαq
mediated intracellular calcium mobilization in HEK-293 cells stably expressing the human 5-
HT2A, human 5-HT2B, and human 5-HT2C (INI) receptors.[21] The results are summarized in
Table 1. In the first round of the functional assays, racemic 12 was found not to activate either
the 5-HT2A or 5-HT2B receptors and to have an EC50 of 19 nM at the 5-HT2C receptor. The
more active enantiomer (+)-12 also showed the expected selectivity profile in these functional
assays. In contrast, the less active isomer (−)-12 had an EC50 of 918 nM in the 5-HT2C assay.
For comparison purposes we also tested the 5-HT2C ligand 2, which is in Phase III clinical
trials for obesity. In our hands this compound has a low nM potency at the 5-HT2C receptor,
however, it is also fairly active at the 5-HT2B subtype, with an EC50 of 85 nM and an Emax of
93%. As such, there may be some risk for possible valvulopathic side effects induced by this
drug. Compound (+)-12 has an even lower selectivity margin towards the 5HT2B-subtype, but
due to its low maximal activity, 21%, we believe this will be a very minor concern, especially
in view of the 2B-antagonist activity described below. Three other known 5-HT2C agonists
Vabicaserin (3) and the Way compounds 4 and 5 along with 5-HT (1) are also included in Table
1 for reference purposes.
In order to further characterize the pharmacology of the lead compounds, both (+)-12 and
(+)-18, which show minimal 5-HT2B activation, were tested for their ability to function as 5-
HT2B antagonists. Compounds (+)-12 and (+)-18 were found to shift the concentration curve
of 5-HT in calcium flux experiments rightwards without depressing the maximal 5-HT
response, indicating fast binding kinetics (Figure 2). Schild analyses yielded pA2 (± SEM)
values of 5.50 ± 0.06, 5.79 ± 0.07, and 5.92 ± 0.02, respectively (n = 3). These results show
that the tested compounds act as moderate potency, full antagonists at the 5-HT2B receptor.
On the basis of their promising in vitro pharmacology, the active enantiomers (+)-12 and
(+)-18 were selected for further in vivo studies. Specifically, we examined the ability of these
compounds to normalize disrupted prepulse inhibition (PPI) in phencyclidine (PCP) treated
animals.[22] The ability to normalize the effects of PCP (an NMDA receptor antagonist)-
induced disruption of PPI in mice is a well accepted model of measuring atypical antipsychotic
activity [23,24] and has been used previously to characterize the antipsychotic activity of 5-
HT2C agonists.[25] We have successfully used an identical PPI testing paradigm previously
to demonstrate clozapine, a classic atypical antipsychotic, robustly normalizes PCP-disrupted
PPI.[26] We tested the ability of compounds (+)-12 and (+)-18 as well as 3 as the reference
compound, to normalize PCP effects on PPI (Figure 3). As is apparent from the accompanying
figures, both (+)-12 and (+)-18 are able to normalize PCP-disrupted PPI at doses of 10 mg/kg
(and are comparable in activity to 3), while at the 5 mg/kg dose level, (+)-12 and 3 are still
effective.
Because of its robust activity at normalizing PCP-disrupted PPI, we carried out cytochrome
P-450 screening, metabolic stability studies, and hERG assays on (+)-12 in order to qualify it
as a possible candidate for further development. In the recombinant CYP inhibition test,
(+)-12 showed relatively low inhibition against CYP2C9 (19.6%), CYP2D6 (27.0%), and
CYP3A4 (21.7% and 25.1% using midazolam and testosterone as the substrates, respectively,
at 10 μM (Table 2). Furthermore, compound (+)-12 had an acceptable microsomal stability in
a 1h assay (90.5% left in human microsomes and 66% in rat, respectively) compared with the
control drug, verapamil (39.6% using human microsomes). Additionally, no hERG inhibition
was detected for (+)-12, (–)-12, or 18, nor for the comparison compounds 2, 3, and 5. However,
4 caused very modest inhibition (3.6 mM, 97%), and the standard cisapride gave full inhibition
(35 nM, 100%).
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In conclusion, our optimization efforts led to the discovery of the highly selective 5-
HTHT2C agonists (±)-12 and (±)-18, and to the identification of (+)-12 and (+)-18 as the more
active enantiomers. Compounds (+)-12 and (+)-18 were as effective as the known reference
compound 3 in the PCP-PPI animal model of antipsychotic drug activity. Compound 3 was
recently in Phase II clinical trials for the treatment of acute exacerbations of schizophrenia.
Compound (+)-12 has an acceptable DMPK profile while showing no adverse side effects in
animals. Compound (+)-12 represents a structurally simple 5-HT2C partial agonist of excellent
potency and high selectivity. The structural relationship of 12 with the marketed monamine
oxidase inhibitor tranylcypromine is also noteworthy, and when combined with the information
now in hand, bodes well for the further development of this class of molecules. The study of
(+)-12 in other animal disease models including cocaine addiction is underway.
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Several recently developed 5-HT2C agonists.
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5-HT2B antagonism (Schild Plot) of compounds (+)-18 (A) and (+)-12 (B). (pA2 (± SEM):
5.79 ± 0.07 and 5.92 ± 0.02 (n = 3)).
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Compounds (+)-12 and (+)-18 normalize PCP-disrupted PPI in mice. Mice were administered
(ip) saline or 6 mg/kg PCP and immediately tested for PPI of the acoustic startle response. (A)
and (B). 30 min pre-treatments of mice with (+)-12 or (+)-18 effectively normalize PCP-
disruption of PPI. (C). Compound 3, a positive reference control compound, also normalizes
PCP-disrupted PPI. *, p < 0.05 versus saline treated animals. Data are the mean ± SEM. N =
9, 10 or 7 animals in each testing group for (+)-12, (+)-18 or 3, respectively.
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Reagents and conditions: (a) Boc2O, triethylamine, CH2Cl2, 0 °C to rt, 5 h. (b) (bromomethyl)
cyclopropane, K2CO3, DMF, 60 °C, 20 h. (c) 2M HCl, rt, 48 h.
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Reagents and conditions: (a) (i) BBr3, CH2Cl2, −78 °C to rt, 6 h; (ii) Boc2O, triethylamine,
CH2Cl2, 0 °C to rt, 1h. (b) Piv-Cl, CH2Cl2, triethylamine, 0 °C to rt, 6 h. (c) (bromomethyl)
cyclopropane, K2CO3, DMF, 60 °C, 20 h. (d) NaOtBu, MeOH, rt, 1 h. (e) 2 M HCl, rt, 48 h.
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Reagents and conditions: (a) 2M HCl, rt, 48 h.
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